Highlights of weekly biotech stock moves

BTG plc (LSE:BTG) was off 12.30p to 344.50p last week after Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Zytiga abiraterone from Johnson & Johnson (NYSE:JNJ) has significant additional benefit over "watchful waiting" to treat chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC) - an indication for which it was approved by the EC in January. J&J has rights from BTG.

Optimer Pharmaceuticals Inc. (NASDAQ:OPTR) gained $0.30 to $14.99 last week although Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Dificlir fidaxomicin from partner Astellas Pharma Inc. (Tokyo:4503) has "no additional benefit" over comparators to treat Clostridium difficile-associated diarrhea (CDAD). Astellas has European rights from Optimer (see B12)...